Endocrine therapy (ET), which includes tamoxifen and aromatase inhibitors (AI) either alone or in combination with other agents, represents the backbone of therapeutic strategies in the management of patients with hormone receptor (HR)-positive breast cancer.1,2,3 Multiple large studies have demonstrated associations of ET with improved survival outcomes among these patients. This evidence concerns the gene CYP19A1 and breast carcinoma.